当前位置： SCI文献检索 > INVESTIGATIONAL NEW DRUGS期刊下所有文献 > Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Abstract：

:Mitoxantrone (Novantrone) and prednimustine (Sterecyt) are both active as single agents in the treatment of unfavorable non-Hodgkin lymphoma (UNHL). The efficacy and toxicity of the combination of these agents (NOSTE) was evaluated in 28 patients with advanced histopathologically proven UNHL who were not eligible for aggressive conventional chemotherapy. The median age was 68, range 45-84. Sixteen patients were previously untreated. Eleven patients had received doxorubicin or epidoxorubicin containing regimens and 1 patient had received CVP as first line therapy. MUGA scan was used in monitoring cardiac function in patients with cardiac risk. Novantrone was administered at a dose of 8 mg/m2 IV on days 1 and 2 and Sterecyt as an absolute dose 100 mg/less than or equal to 1.6 m2-150 mg/greater than 1.6 m2 on days 1 through 5. The regimen was repeated every 4th week. The number of courses per patient ranged from 2 to 10. Objective response was obtained in 22 (78%) patients (20 CR and 2 PR). No response occurred in 6 patients (4 SD, 2 PD). Decreased left ventricular ejection fraction was recorded in 1 patient who suffered from asthma and ischemic heart disease. Hematological toxicity was tolerable. Gastrointestinal toxicity was rare. No hair loss was observed. After a median follow-up of 28 months the crude survival was 46%. Twelve of twenty complete responders are still in remission, the median duration of remission is 28.3 months, range 15-37. NOSTE in this pilot study showed a high response rate, good tolerance and mild toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Invest New Drugs

journal_title

Investigational new drugs

authors

Landys KE

doi

10.1007/BF00195368

subject

Has Abstract

pub_date

1988-06-01 00:00:00

pages

105-13

issue

2

eissn

0167-6997

issn

1573-0646

journal_volume

6

pub_type

杂志文章

相关文献

INVESTIGATIONAL NEW DRUGS文献大全
  • Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.

    abstract：:Compared to doxorubicin, equimolar epirubicin toxicity is reduced by about 50% by the epimerization of a hydrogen and hydroxyl group at the 4' position of the anthracycline sugar moiety. The circadian timing of doxorubicin administration markedly affects its lethal and sub-lethal bone marrow and gut toxicities in mice...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00173645

    authors： Mormont MC,von Roemeling R,Sothern RB,Berestka JS,Langevin TR,Wick M,Hrushesky WJ

    更新日期：1988-12-01 00:00:00

  • Cellular pharmacology of fluorinated pyrimidines in vivo in man.

    abstract：:Fluorinated pyrimidines, particularly 5-fluorouracil (FUra), have been the subject of intense and almost continuous basic and clinical study since development in the late 1950's by Dr. Charles Heidelberger. Despite this intensive effort, the most important mechanisms by which FUra influences tumor growth in individual...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1007/BF00178188

    authors： Kovach JS,Beart RW Jr

    更新日期：1989-04-01 00:00:00

  • Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

    abstract：:The combination of anti-cancer drugs with nutritional factors is a potential strategy for improving the efficacy of chemotherapy, particularly for hepatocellular carcinoma because its conventional therapies are mostly ineffective. Using a highly invasive hepatoma SK-Hep-1 cell line, we investigated the possible synerg...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-011-9727-0

    authors： Huang CS,Lyu SC,Hu ML

    更新日期：2012-08-01 00:00:00

  • Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

    abstract：:Background The hexapeptide 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) was isolated from a peptide library constructed to identify peptide-based transport inhibitors of multidrug resistance (MDR) efflux pumps including P-glycoprotein and Multidrug Resistance-associated Protein 1. 4A6 proved to be a subst...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-018-0569-x

    authors： Oerlemans R,Berkers CR,Assaraf YG,Scheffer GL,Peters GJ,Verbrugge SE,Cloos J,Slootstra J,Meloen RH,Shoemaker RH,Dijkmans BAC,Scheper RJ,Ovaa H,Jansen G

    更新日期：2018-10-01 00:00:00

  • Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer.

    abstract：:Sphingosine-1-phosphate (S1P) is an important regulator of cancer development and progression. Its cellular concentration is controlled predominantly by sphingosine kinase (SK) and sphingosine-1-phosphate lyase (SPL). In the current study we showed that mRNA expressions for both SK and SPL were up-regulated throughout...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9375-9

    authors： Ling B,Chen L,Alcorn J,Ma B,Yang J

    更新日期：2011-04-01 00:00:00

  • Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.

    abstract：:Epidermal growth factor receptor (EGFR) gene mutations activate the KRAS-RAF-MEK-ERK pathway in lung cancer cells. EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib induce apoptosis of cancer cells, but prolonged treatment is often associated with acquired resistance. Here, we identified a novel MEK1/2 inhibito...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-013-0030-0

    authors： Song JY,Kim CS,Lee JH,Jang SJ,Lee SW,Hwang JJ,Lim C,Lee G,Seo J,Cho SY,Choi J

    更新日期：2013-12-01 00:00:00

  • Recombinant gamma interferon in advanced breast cancer: a phase II trial.

    abstract：:Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 X 10(7) international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patients had a performance...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00173511

    authors： Muss HB,Caponera M,Zekan PJ,Jackson DV Jr,Stuart JJ,Richards F,Cooper MR,Levin EA,Reich SD,Capizzi RL

    更新日期：1986-01-01 00:00:00

  • Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.

    abstract：:L1210 leukemia cells, because of their rapid growth rate in suspension culture and high growth fraction, are ideally suited to screen in vitro for cytotoxic compounds. Although L1210 cells may mimic rapidly growing tumors, they have not been effective in selecting agents active against slow growing solid tumors. We ex...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00175291

    authors： Badiner GJ,Hamilton RD,Li LH,Bhuyan BK

    更新日期：1987-01-01 00:00:00

  • Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound.

    abstract：:An HPLC analytical method was applied to the determination of plasma concentrations of 5,6-dihydro-5-azacytidine (NSC 264880, DHAC) in two foxhounds after a rapid intravenous infusion of 300 mg/kg DHAC. The dose employed is the mouse equivalent LD10 dose which results in mild reversible toxicity in the dog. The declin...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00180191

    authors： Malspeis L,Cheng H,Staubus AE

    更新日期：1983-01-01 00:00:00

  • Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.

    abstract：:A phase I trial of first-line vorinostat, an orally bio-available histone deacetylase inhibitor, in combination with capecitabine plus cisplatin (XP) was performed to assess recommend phase II trial dose in patients with advanced gastric cancer. Five dose levels of three-weekly vorinostat-XP were tested; vorinostat wa...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-013-9983-2

    authors： Yoo C,Ryu MH,Na YS,Ryoo BY,Lee CW,Maeng J,Kim SY,Koo DH,Park I,Kang YK

    更新日期：2014-04-01 00:00:00

  • Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

    abstract：:Gemcitabine (GEM) is a novel nucleoside analogue with a unique mechanism of action. Preliminary studies have shown a mild, schedule-dependent toxic profile with a broad range of MTDs and promising antitumor activity in various solid tumors. This phase I study describes the infusion length-effect relationships of low- ...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005817024382

    authors： Pollera CF,Ceribelli A,Crecco M,Oliva C,Calabresi F

    更新日期：1997-01-01 00:00:00

  • Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.

    abstract：:In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluab...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00175387

    authors： Stehman FB,Blessing JA,Homesley HD,Currie JL,Yordan EL

    更新日期：1984-01-01 00:00:00

  • A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.

    abstract：:Background PF-06840003 is a highly selective indoleamine 2, 3-dioxygenase (IDO1) inhibitor with antitumor effects in preclinical models. This first-in-human phase 1 study evaluated safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy in recurrent malignant glioma to determine the maximum tolerated dose ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-00950-1

    authors： Reardon DA,Desjardins A,Rixe O,Cloughesy T,Alekar S,Williams JH,Li R,Taylor CT,Lassman AB

    更新日期：2020-12-01 00:00:00

  • Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:Docetaxel-prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated orteronel plus DP in mCRPC ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-014-0199-x

    authors： Petrylak DP,Gandhi JG,Clark WR,Heath E,Lin J,Oh WK,Agus DB,Carthon B,Moran S,Kong N,Suri A,Bargfrede M,Liu G

    更新日期：2015-04-01 00:00:00

  • Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.

    abstract：BACKGROUND:Gemcitabine is a pro-drug that has to be phosphorylated to gemcitabine-triphosphate in order to exhibit its antineoplastic activity. This reaction involves the enzyme deoxycytidine kinase which is saturated at plasma concentrations following standard 30-min infusions. Pharmacological studies indicate that pr...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10637-005-5859-4

    authors： Schmid P,Schweigert M,Beinert T,Flath B,Sezer O,Possinger K

    更新日期：2005-03-01 00:00:00

  • The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.

    abstract：:Background Treatment of recurrent, unresectable granulosa cell tumor (GCT) of the ovary can be challenging. Given the rarity of the tumor, alternative therapies have been difficult to evaluate in large prospective clinical trials. Currently, to our knowledge, there are no reports of the use of immune checkpoint inhibi...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-01043-9

    authors： How JA,Jazaeri A,Westin SN,Sood AK,Ramondetta LM,Xu M,Abonofal A,Karp DD,Subbiah V,Stephen B,Rodon JA,Yang F,Naing A

    更新日期：2021-01-07 00:00:00

  • Novel palladium (II) complexes with tetradentate thiosemicarbazones. Synthesis, characterization, in vitro cytotoxicity and xanthine oxidase inhibition.

    abstract：:In vitro cytotoxicity and xanthine oxidase inhibition capabilities were investigated for five palladium (II) chelate complexes. The palladium complexes were synthesized by starting from S-alkyl-thiosemicarbazones where the alkyl component is methyl, ethyl, propyl or butyl. The solid complexes are characterized by elem...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-019-00751-1

    authors： Özerkan D,Ertik O,Kaya B,Kuruca SE,Yanardag R,Ülküseven B

    更新日期：2019-12-01 00:00:00

  • T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.

    abstract：:T cells are important effectors in anti-tumor immunity, and aberrant expression of B7 family members may contribute to tumor evasion. In this study, we analyzed expression of costimulatory molecules on human hematologic tumor cells and explored whether B7-H3, a member of the B7 superfamily, is an effective target for ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-019-00819-y

    authors： Sun X,Yu Y,Ma L,Xue X,Gao Z,Ma J,Zhang M

    更新日期：2020-06-01 00:00:00

  • Effects of diflubenzuron and clanfenur on mouse bone marrow cells.

    abstract：:Diflubenzuron (DFB) and Clanfenur (CFN) belong to a group of compounds called Benzoylphenyl Ureas (BPUs). Several BPUs regulate cell growth in insects and/or inhibit growth of B-16 murine melanomas. In view of potential clinical use for these compounds, DFB and CFN were selected as examples of BPUs and tested for effe...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00874426

    authors： Jenkins VK,Juneja HS,Ives K,Lee S,Perry RR

    更新日期：1993-11-01 00:00:00

  • Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.

    abstract：:Ergot alkaloids are psychoactive and vasoconstricting agents of the fungus Claviceps purpurea causing poisoning such as ergotism in medieval times (St. Anthony's Fire). This class of substances also inhibits tumor growth in vitro and in vivo, though the underlying mechanisms are unclear as yet. We investigated six erg...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-014-0168-4

    authors： Mrusek M,Seo EJ,Greten HJ,Simon M,Efferth T

    更新日期：2015-02-01 00:00:00

  • The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

    abstract：:As HER2 is a client protein of the molecular chaperone Hsp90, targeting Hsp90 may be beneficial in HER2-positive breast cancer. In this study, the activity of the Hsp90 inhibitor NVP-AUY922 was assessed in HER2 overexpressing breast cancer cell lines, including two cell line models of acquired trastuzumab-resistance. ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-017-0556-7

    authors： Canonici A,Qadir Z,Conlon NT,Collins DM,O'Brien NA,Walsh N,Eustace AJ,O'Donovan N,Crown J

    更新日期：2018-08-01 00:00:00

  • Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.

    abstract：:Background This Phase 1b study aimed to determine the recommended Phase 2 dose of LY2334737, an oral pro-drug of gemcitabine, in combination with capecitabine, an oral pro-drug of 5-fluorouracil, in patients with advanced solid tumors. In addition, pharmacokinetics (PK) and tumor response were evaluated. Patients and ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-015-0207-9

    authors： Infante JR,Benhadji KA,Dy GK,Fetterly G,Ma WW,Bendell J,Callies S,Adjei AA

    更新日期：2015-04-01 00:00:00

  • A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.

    abstract：:The purpose of this study was to assess the efficacy and safety of bevacizumab plus cetuximab with or without gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients with locally advanced or metastatic pancreatic adenocarcinoma, previously untreated, were randomized to bevacizumab (10 mg/kg q2w) plus...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10637-011-9691-8

    authors： Ko AH,Youssoufian H,Gurtler J,Dicke K,Kayaleh O,Lenz HJ,Keaton M,Katz T,Ballal S,Rowinsky EK

    更新日期：2012-08-01 00:00:00

  • Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.

    abstract：:Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab plus carboplatin and etoposide in SCL...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-00983-6

    authors： Ishii H,Azuma K,Kawahara A,Matsuo N,Tokito T,Hoshino T

    更新日期：2020-08-11 00:00:00

  • Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.

    abstract：:Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9, non-anthracycline c...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00173763

    authors： McGuire WP,Blessing JA,Berman ML

    更新日期：1989-11-01 00:00:00

  • Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.

    abstract：:Background AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor (FGFR) inhibitor in clinical development for treating tumours with a range of FGFR aberrations, including FGFR mutations, amplifications and fusions. Methods This open-label, Phase I, multicentre study (NCT01213160) evaluated the ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-016-0416-x

    authors： Saka H,Kitagawa C,Kogure Y,Takahashi Y,Fujikawa K,Sagawa T,Iwasa S,Takahashi N,Fukao T,Tchinou C,Landers D,Yamada Y

    更新日期：2017-08-01 00:00:00

  • Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

    abstract：:Gemcitabine is a deoxycytidine (dCyd) analog with activity in leukemia and solid tumors, which requires phosphorylation by deoxycytidine kinase (dCK). Decreased membrane transport is a mechanism of resistance to gemcitabine. In order to facilitate gemcitabine uptake and prolong retention in the cell, a lipophilic pro-...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9377-7

    authors： Bergman AM,Adema AD,Balzarini J,Bruheim S,Fichtner I,Noordhuis P,Fodstad O,Myhren F,Sandvold ML,Hendriks HR,Peters GJ

    更新日期：2011-06-01 00:00:00

  • Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.

    abstract：PURPOSE:To evaluate the impact of flutamide on survival of patients with unresectable pancreatic cancer. METHODS:This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10637-005-3536-2

    authors： Negi SS,Agarwal A,Chaudhary A

    更新日期：2006-05-01 00:00:00

  • Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

    abstract：BACKGROUND:Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS. METHODS:Patients with advanced, recurrent, or ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-006-9035-2

    authors： Suppiah R,Wood L,Elson P,Budd GT

    更新日期：2006-11-01 00:00:00

  • A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

    abstract：BACKGROUND:We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XEL...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-009-9363-0

    authors： Kim C,Lee JL,Ryu MH,Chang HM,Kim TW,Lim HY,Kang HJ,Park YS,Ryoo BY,Kang YK

    更新日期：2011-04-01 00:00:00